Skip to main content

Practical Aspects of Prostaglandin E1 before and after Solid Organ Transplantation

  • Chapter
Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research

Abstract

Prostaglandins and analogues for therapeutic use gained importance in the early eighties, when a substantial number of clinical studies about their therapeutical effects was published6, 12, 17, 22. Out of the huge family of prostanoids, prostaglandins E1 (PG E1) and I2 and their synthetical analogues are the most important substances in clinical practice in the field of solid organ transplantation. Organ procurement and organ preservation4, 5, 9, 15, 19 as well as treatment of primary graft failure8, 10 have been described as possible indications for PG E1. Vasodilating effects of prostaglandins are mediated by increasing cAMP levels in vascular smooth muscle cells. This mediation by cAMP is shared with beta-agonists and phosphodiesterase-inhibitors, but not with nitrates and nitric oxide3, 14, 21. Treatment of elevated pulmonary vascular resistance (PVR), which is frequently needed after heart transplantation (HTX), and in the pretransplant evaluation as well as bridging to transplan-tation1, 7, 20 has been the indication for PG E1 in our patient cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armitage G., Hardesty R. et al., Prostaglandin E1: An effective treatment of right heart failure after cardiac transplantation. J Heart Transplant 6:348–51 (1987)

    PubMed  CAS  Google Scholar 

  2. Cawello W., Leonhardt A., Schweer H. et al, Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Br J Pharmacol. 40(3): 273–6 (1995)

    Article  CAS  Google Scholar 

  3. Fullerton D., Hahn A. et al, Pulmonary vascular smooth muscle cell relaxation by cGMP-versus cAMP-mediated mechanisms. J Surg Res. 57(2): 259–63 (1994)

    Article  PubMed  CAS  Google Scholar 

  4. Harjula A., Baldwin J. et al, Clinical heart lung preservation with Prostaglandin E1. Transpl Proc. 19: 4101 (1987)

    CAS  Google Scholar 

  5. Hide EJ., Ney P., Piper J. et al., Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. BrJ Pharmacol. 116(5): 2435–40 (1995)

    Article  CAS  Google Scholar 

  6. Higenbottam T, Wheeldon D et al., Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (Prostacyclin). Lancet 12: 1046–7 (1984)

    Article  Google Scholar 

  7. Iberer F., Wasler A. et al., Prostaglandin E1 induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant 12(2): 173–8 (1993)

    PubMed  CAS  Google Scholar 

  8. Iberer F., Müller H. et al., Prostaglandin E1 in der Therapie der Abstoßung und des pulmonalen Hypertonus im Rahmen der Herztransplantation. Immundiagnostik und Immuntherapie in der modernen Intensivmedizin, Vogt S., ed., Pabst-Verlag, Lengerich (1993)

    Google Scholar 

  9. Kim Y., Kai T. et al., Hepatoprotection by a PG I2 analogue in complete wann ischemia of the pig liver. Prostanoid release from the reperfused liver. Transplantation 58(8): 875–9 (1994)

    Article  PubMed  CAS  Google Scholar 

  10. Moran M., Mozes M. et al., Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 322: 1183–88 (1990)

    Article  PubMed  CAS  Google Scholar 

  11. Murali S., Uretsky B., Armitage J. et al., Utility of Prostaglandin E1 in the Pretransplantation Evaluation of Heart Failure Patients with Significant Pulmonary Hypertension. J Heart Lung Transplant. 11: 716–23(1991)

    Google Scholar 

  12. Naeije R., Melot C et al., Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Despir Dis. 125: 1–5 (1982)

    CAS  Google Scholar 

  13. Pacher R., Globits S., Wutte M. et al., Beneficial hemodynamic effects of prostaglandin E1 infusion in catecholamine-dependent heart failure: results of a prospective, randomized controlled study. Crit Care Med. 22(7): 1084–90 (1994)

    Article  PubMed  CAS  Google Scholar 

  14. Prielipp R., McLean R. et al., Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin and nifedipin in experimental porcine pulmonary hypertension. Crit Care Med. 19(1): 60–7 (1991)

    Article  PubMed  CAS  Google Scholar 

  15. Quiroga J., Prieto J., Liver cytoprotection by prostaglandins. Pharmacol Ther. 58(1): 67–91 (1993)

    Article  PubMed  CAS  Google Scholar 

  16. Schweer H., Cawello W., Seyberth HW, Gas chromatogryphy negative ion chemical ionization triple quadrupole mass spectometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2, 3, 4, 5, 20-pentanor-19-carboprostanoic acid in plasma. Prostaglandins Leukot Essent Fatty Acids. 51(6): 401–5(1994)

    Article  PubMed  CAS  Google Scholar 

  17. Sinzinger H., Rogatti W., Prostaglandin E1 in der Therapie der peripheren arteriellen Durchblutungsstörung. Wiener Klinische Wochenschrift 103/18: 558–565 (1991)

    PubMed  CAS  Google Scholar 

  18. Sorbara C, Pitarello D. et al., Prostaglandine in der Intensivmedizin und bei Herztransplantationen. Translation from A.P.I. C.E; Vol. 8: 327–337 (1993)

    Google Scholar 

  19. Ueno T., Horita K. et al., The effect of Prostaglandin E1 on heart preservation. Transplantation 54(3): 418–22 (1992)

    Article  PubMed  CAS  Google Scholar 

  20. Vincent J., Carlier E. et al., Prostaglandin E1 infusion for right ventricular failure after after cardiac transplantation. J Thorac Cardiovasc Surgery. 103: 33–39 (1992)

    CAS  Google Scholar 

  21. Warren J., Wilson A. et al., Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J. 7(14): 1394–400 (1993)

    PubMed  CAS  Google Scholar 

  22. Watkins W., Peterson M. et al., Prostacyclin and Prostaglandin E1 for severe idiopathic pulmonary hypertension. Lancet I. 1083 (1981)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Müller, H. et al. (1997). Practical Aspects of Prostaglandin E1 before and after Solid Organ Transplantation. In: Sinzinger, H., Samuelsson, B., Vane, J.R., Paoletti, R., Ramwell, P., Wong, P.YK. (eds) Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Advances in Experimental Medicine and Biology, vol 433. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1810-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1810-9_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1812-3

  • Online ISBN: 978-1-4899-1810-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics